MARKET

URGN

URGN

Urogen Pharma
NASDAQ
14.26
+0.02
+0.14%
Closed 18:42 04/18 EDT
OPEN
14.36
PREV CLOSE
14.24
HIGH
14.54
LOW
13.96
VOLUME
315.35K
TURNOVER
0
52 WEEK HIGH
24.13
52 WEEK LOW
8.69
MARKET CAP
486.58M
P/E (TTM)
-4.0215
1D
5D
1M
3M
1Y
5Y
UroGen Pharma Price Target Maintained With a $54.00/Share by HC Wainwright & Co.
Dow Jones · 1d ago
HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $54 Price Target
Benzinga · 1d ago
Buy Rating Affirmed for Urogen Pharma Amid Promising Clinical Data and Strategic Conference Presentations
TipRanks · 1d ago
UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers
New data on investigational drug UGN-102 (mitomycin) and JELMYTO will be presented at the American Urological Association (AUA) 2024 Annual Meeting in San Antonio, Texas. UroGen anticipates completing its new drug application for ugn-102 in September 2024. The drug is in Phase 3 development for the treatment of LG-IR-NMIBC.
Barchart · 2d ago
UroGen Announces FDA Acceptance Of IND Application For UGN-103, A Next Generation Mitomycin-Based Formulation For Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
UroGen plans to initiate a Phase 3 study to explore the safety and efficacy of UGN-103 in 2024. Anticipated advantages include a new 80 mg mitomycin dosage strength for low-grade intermediate-risk non-muscle invasive bladder cancer. The FDA accepted the Company's Investigational New Drug application for Ugn-103. UroGen is a biotech company dedicated to developing and commercializing novel cancer treatments.
Benzinga · 4d ago
UROGEN PHARMA LTD - FOR UGN-102 POTENTIAL FDA DECISION AS EARLY AS Q1 OF 2025 IF PRIORITY REVIEW IS GRANTED BY FDA
Reuters · 4d ago
Weekly Report: what happened at URGN last week (0408-0412)?
Weekly Report · 4d ago
Two Buys; Two Holds, by Oppenheimer
Two Buys; Two Holds, by Oppenheimer analysts provided updates on five stocks -- two buys and two holds. All five of these companies are rated outperform. Cloudflare Inc. Class A has corrected into its $91 support. CarMax, SEIC, TRU, NET, URGN are among the five companies.
Seeking Alpha · 04/09 13:35
More
About URGN
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).

Webull offers Urogen Pharma Ltd stock information, including NASDAQ: URGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, URGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading URGN stock methods without spending real money on the virtual paper trading platform.